SMT202400104T1 - Composizioni farmaceutiche per politerapia - Google Patents
Composizioni farmaceutiche per politerapiaInfo
- Publication number
- SMT202400104T1 SMT202400104T1 SM20240104T SMT202400104T SMT202400104T1 SM T202400104 T1 SMT202400104 T1 SM T202400104T1 SM 20240104 T SM20240104 T SM 20240104T SM T202400104 T SMT202400104 T SM T202400104T SM T202400104 T1 SMT202400104 T1 SM T202400104T1
- Authority
- SM
- San Marino
- Prior art keywords
- pharmaceutical compositions
- combination therapy
- therapy
- combination
- pharmaceutical
- Prior art date
Links
- 238000002648 combination therapy Methods 0.000 title 1
- 239000008194 pharmaceutical composition Substances 0.000 title 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/575—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of three or more carbon atoms, e.g. cholane, cholestane, ergosterol, sitosterol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/13—Amines
- A61K31/155—Amidines (), e.g. guanidine (H2N—C(=NH)—NH2), isourea (N=C(OH)—NH2), isothiourea (—N=C(SH)—NH2)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/4985—Pyrazines or piperazines ortho- or peri-condensed with heterocyclic ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
- A61K31/7048—Compounds having saccharide radicals and heterocyclic rings having oxygen as a ring hetero atom, e.g. leucoglucosan, hesperidin, erythromycin, nystatin, digitoxin or digoxin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/22—Hormones
- A61K38/26—Glucagons
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
- A61K47/542—Carboxylic acids, e.g. a fatty acid or an amino acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07J—STEROIDS
- C07J9/00—Normal steroids containing carbon, hydrogen, halogen or oxygen substituted in position 17 beta by a chain of more than two carbon atoms, e.g. cholane, cholestane, coprostane
- C07J9/005—Normal steroids containing carbon, hydrogen, halogen or oxygen substituted in position 17 beta by a chain of more than two carbon atoms, e.g. cholane, cholestane, coprostane containing a carboxylic function directly attached or attached by a chain containing only carbon atoms to the cyclopenta[a]hydrophenanthrene skeleton
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07J—STEROIDS
- C07J51/00—Normal steroids with unmodified cyclopenta(a)hydrophenanthrene skeleton not provided for in groups C07J1/00 - C07J43/00
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Organic Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Diabetes (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Endocrinology (AREA)
- Gastroenterology & Hepatology (AREA)
- Obesity (AREA)
- Hematology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Immunology (AREA)
- Zoology (AREA)
- Emergency Medicine (AREA)
- Child & Adolescent Psychology (AREA)
- Molecular Biology (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201562144040P | 2015-04-07 | 2015-04-07 | |
| PCT/US2016/026146 WO2016164413A1 (en) | 2015-04-07 | 2016-04-06 | Pharmaceutical compositions for combination therapy |
| EP16777168.2A EP3280421B1 (en) | 2015-04-07 | 2016-04-06 | Pharmaceutical compositions for combination therapy |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| SMT202400104T1 true SMT202400104T1 (it) | 2024-05-14 |
Family
ID=57072872
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| SM20240104T SMT202400104T1 (it) | 2015-04-07 | 2016-04-06 | Composizioni farmaceutiche per politerapia |
Country Status (25)
| Country | Link |
|---|---|
| US (1) | US10894054B2 (https=) |
| EP (1) | EP3280421B1 (https=) |
| JP (1) | JP6879931B2 (https=) |
| KR (1) | KR20170132879A (https=) |
| CN (1) | CN107613986A (https=) |
| AR (1) | AR104195A1 (https=) |
| AU (1) | AU2016246524B2 (https=) |
| BR (1) | BR112017021311A2 (https=) |
| CA (1) | CA2981507A1 (https=) |
| CL (2) | CL2017002538A1 (https=) |
| CO (1) | CO2017010292A2 (https=) |
| CR (1) | CR20170456A (https=) |
| EA (1) | EA036757B1 (https=) |
| EC (1) | ECSP17073004A (https=) |
| ES (1) | ES2974281T3 (https=) |
| IL (2) | IL254772A0 (https=) |
| MA (1) | MA41083A1 (https=) |
| MX (1) | MX2017012893A (https=) |
| NI (1) | NI201700121A (https=) |
| PE (1) | PE20180034A1 (https=) |
| SM (1) | SMT202400104T1 (https=) |
| SV (1) | SV2017005539A (https=) |
| TN (1) | TN2017000426A1 (https=) |
| TW (1) | TW201642869A (https=) |
| WO (1) | WO2016164413A1 (https=) |
Families Citing this family (32)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US9719068B2 (en) | 2010-05-06 | 2017-08-01 | Children's Hospital Medical Center | Methods and systems for converting precursor cells into intestinal tissues through directed differentiation |
| CN106661548B (zh) | 2014-05-28 | 2020-12-11 | 儿童医院医疗中心 | 用于经由定向分化将前体细胞转化为胃组织的方法和系统 |
| JP6804438B2 (ja) | 2014-10-17 | 2020-12-23 | チルドレンズ ホスピタル メディカル センター | 多能性幹細胞を使用するヒト小腸のｉｎ ｖｉｖｏモデル、並びにそれを作製、及び使用する方法 |
| EA201791982A1 (ru) | 2015-03-09 | 2020-02-17 | Интекрин Терапьютикс, Инк. | Способы лечения неалкогольной жировой болезни печени и/или липодистрофии |
| WO2017182873A2 (en) | 2016-04-19 | 2017-10-26 | Ureka Sarl | Peptide-oligourea foldamer compounds and methods of their use |
| JP7221694B2 (ja) | 2016-04-28 | 2023-02-14 | ノヴォ ノルディスク アー／エス | 心血管状態におけるセマグルチド |
| ES2929758T3 (es) | 2016-05-05 | 2022-12-01 | Childrens Hospital Med Ct | Métodos para la fabricación in vitro de tejido del fondo gástrico y composiciones relacionadas con el mismo |
| KR102729404B1 (ko) * | 2016-11-04 | 2024-11-14 | 칠드런즈 호스피탈 메디칼 센터 | 간 유사 장기 조성물 및 이를 제조 및 사용하는 방법 |
| JP7068305B2 (ja) | 2016-12-05 | 2022-05-16 | チルドレンズ ホスピタル メディカル センター | 結腸オルガノイドならびにその作製方法および使用方法 |
| AU2018249822A1 (en) | 2017-04-03 | 2019-10-31 | Coherus Biosciences Inc. | PPArgamma agonist for treatment of progressive supranuclear palsy |
| US12281334B2 (en) | 2017-04-14 | 2025-04-22 | Children's Hospital Medical Center | Multi donor stem cell compositions and methods of making same |
| EP3694603B1 (en) | 2017-10-10 | 2026-04-08 | Children's Hospital Medical Center | Esophageal tissue and/or organoid compositions and methods of making same |
| US12379372B2 (en) | 2017-12-21 | 2025-08-05 | Children's Hospital Medical Center | Digitalized human organoids and methods of using same |
| CA3101274A1 (en) * | 2018-04-24 | 2019-10-31 | Ph Pharma Co., Ltd. | Use of neutrophil elastase inhibitors in liver disease |
| KR102887406B1 (ko) | 2018-07-26 | 2025-11-19 | 칠드런즈 호스피탈 메디칼 센터 | 간-담도-췌장 조직 및 이를 제조하는 방법 |
| GB201812382D0 (en) | 2018-07-30 | 2018-09-12 | Nzp Uk Ltd | Compounds |
| AU2019339410A1 (en) | 2018-09-12 | 2021-04-15 | Children's Hospital Medical Center | Organoid compositions for the production of hematopoietic stem cells and derivatives thereof |
| EP3866776A4 (en) * | 2018-10-18 | 2022-08-10 | Avolynt | USE OF SGLT2 INHIBITORS TO TREAT PRIMARY SCLEROSING CHOLANGITIS |
| CN113329754A (zh) | 2018-11-20 | 2021-08-31 | 麻雀制药股份有限公司 | 用于施用皮质类固醇的方法 |
| WO2020108830A1 (en) * | 2018-11-30 | 2020-06-04 | Ureka Sarl | Peptide-oligourea foldamer compounds and methods of their use |
| WO2020160371A1 (en) | 2019-02-01 | 2020-08-06 | The University Of Hong Kong | Innervated organoid compositions and methods of making same |
| WO2020198383A1 (en) * | 2019-03-26 | 2020-10-01 | Intercept Pharmaceuticals, Inc. | Methods of diagnosis and treatment of liver diseases using obeticholic acid |
| WO2020205024A1 (en) * | 2019-04-04 | 2020-10-08 | Coherus Biosciences, Inc. | Compositions and methods to treat non-alcoholic fatty liver diseases (nafld) |
| WO2020243613A1 (en) | 2019-05-31 | 2020-12-03 | Children's Hospital Medical Center | Methods of generating and expanding hematopoietic stem cells |
| WO2020243633A1 (en) | 2019-05-31 | 2020-12-03 | Children's Hospital Medical Center | Shaped organoid compositions and methods of making same |
| WO2021029656A1 (ko) * | 2019-08-14 | 2021-02-18 | 주식회사 바이오톡스텍 | 하이드로퀴논 유도체, 및 오베티콜릭산을 포함하는 비알콜성 지방간염의 예방 또는 치료용 약학조성물 |
| JP2024502673A (ja) * | 2021-01-14 | 2024-01-22 | ウエヌイグレックオ・ファーマ | Ｈｂｖ感染の処置のためのｆｘｒアゴニストとｉｆｎの相乗効果 |
| WO2022152773A1 (en) * | 2021-01-14 | 2022-07-21 | Enyo Pharma | Method for treating chronic kidney diseases |
| WO2023225507A1 (en) * | 2022-05-16 | 2023-11-23 | Sparrow Pharmaceuticals, Inc. | Methods and compositions for treating glucocorticoid excess |
| EP4525983A4 (en) | 2022-05-16 | 2025-09-03 | Sparrow Pharmaceuticals Inc | METHODS AND COMPOSITIONS FOR TREATING GLUCOCORTICOID EXCESS |
| CA3258674A1 (en) * | 2022-06-08 | 2023-12-14 | Kojin Therapeutics, Inc. | METHODS AND COMPOSITIONS FOR INITIATING, REGULATING AND MODULATING WEIGHT LOSS AND THEIR THERAPEUTIC APPLICATIONS |
| CN120789063B (zh) * | 2025-08-15 | 2026-02-10 | 北京大学第三医院（北京大学第三临床医学院） | 一种药物组合物、制剂及其制备方法和应用 |
Family Cites Families (46)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5747445A (en) * | 1993-06-24 | 1998-05-05 | Astra Aktiebolag | Therapeutic preparation for inhalation |
| US20030109467A1 (en) | 2001-11-15 | 2003-06-12 | Isis Pharmaceuticals Inc. | Antisense modulation of human FXR expression |
| DE69940958D1 (de) | 1998-12-23 | 2009-07-16 | Glaxo Group Ltd | Bestimmungsmethode fur liganden der nuklearen rezeptoren |
| WO2000040965A1 (en) | 1999-01-07 | 2000-07-13 | Tularik, Inc. | Fxr receptor-mediated modulation of cholesterol metabolism |
| US20020132223A1 (en) | 1999-03-26 | 2002-09-19 | City Of Hope | Methods for modulating activity of the FXR nuclear receptor |
| SI1169312T1 (en) | 1999-03-29 | 2005-02-28 | F. Hoffmann-La Roche Ag | Glucokinase activators |
| AU2001288623A1 (en) | 2000-09-05 | 2002-03-22 | Tularik, Inc. | Fxr modulators |
| ES2248581T3 (es) | 2001-03-12 | 2006-03-16 | Intercept Pharmaceuticals, Inc. | Esteroides como agonistas de fxr. |
| ATE381542T1 (de) | 2001-08-13 | 2008-01-15 | Phenex Pharmaceuticals Ag | Nr1h4-kern-rezeptor-bindende verbindungen |
| AU2003228485A1 (en) | 2002-04-12 | 2003-10-27 | The University Of Chicago | Farnesoid x-activated receptor agonists |
| EP1679965A4 (en) | 2003-08-01 | 2009-05-27 | Janssen Pharmaceutica Nv | SUBSTITUTED ANELLIERED HETEROCYCLIC C-GLYCOSIDES |
| RS20060320A (sr) | 2003-08-01 | 2008-08-07 | Janssen Pharmaceutica N.V., | Supstituisani indazol-o-glukozidi |
| EP1568706A1 (en) | 2004-02-26 | 2005-08-31 | Intercept Pharmaceuticals, Inc. | Novel steroid agonist for FXR |
| PL1734970T3 (pl) | 2004-03-12 | 2015-05-29 | Intercept Pharmaceuticals Inc | Leczenie zwłóknienia z zastosowaniem ligandów FXR |
| US20060252670A1 (en) * | 2004-10-14 | 2006-11-09 | Intercept Pharmaceuticals Inc. | Method of reducing drug-induced adverse side effects in a patient |
| ITMI20050912A1 (it) | 2005-05-19 | 2006-11-20 | Erregierre Spa | Processo di preparazione di acidi 3-a-ya(b)-diidrossi-6-a(b)-alchil-5b-colanici |
| ES2736184T3 (es) * | 2005-08-19 | 2019-12-26 | Amylin Pharmaceuticals Llc | Exendina para el tratamiento de la diabetes y la reducción del peso corporal |
| WO2007022518A2 (en) * | 2005-08-19 | 2007-02-22 | Amylin Pharmaceuticals, Inc. | New uses of glucoregulatory proteins |
| WO2007076260A2 (en) * | 2005-12-19 | 2007-07-05 | Smithkline Beecham Corporation | Farnesoid x receptor agonists |
| CN101395170A (zh) | 2006-02-14 | 2009-03-25 | 英特塞普特药品公司 | 用于预防或治疗fxr介导的疾病或状态的作为fxr配体的胆汁酸衍生物 |
| CN101448791B (zh) | 2006-05-24 | 2011-11-16 | 伊莱利利公司 | Fxr激动剂 |
| TW200812982A (en) | 2006-05-24 | 2008-03-16 | Lilly Co Eli | Compounds and methods for modulating FXR |
| US7932244B2 (en) | 2006-06-27 | 2011-04-26 | Intercept Pharmaceuticals, Inc. | Bile acid derivatives as FXR ligands for the prevention or treatment of FXR-mediated diseases or conditions |
| EP1886685A1 (en) | 2006-08-11 | 2008-02-13 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Methods, uses and compositions for modulating replication of hcv through the farnesoid x receptor (fxr) activation or inhibition |
| EP1894924A1 (en) | 2006-08-29 | 2008-03-05 | Phenex Pharmaceuticals AG | Heterocyclic FXR binding compounds |
| EP1894928A1 (en) | 2006-08-29 | 2008-03-05 | PheneX Pharmaceuticals AG | Heterocyclic fxr binding compounds |
| KR20090094125A (ko) | 2006-12-08 | 2009-09-03 | 엑셀리시스, 인코포레이티드 | Ｌｘｒ 및 ｆｘｒ 조절자 |
| US20080299118A1 (en) | 2007-06-01 | 2008-12-04 | Wyeth | FXR Agonists for the Treatment of Malignancies |
| US20080300235A1 (en) | 2007-06-01 | 2008-12-04 | Wyeth | FXR Agonists for Reducing LOX-1 Expression |
| TW200906823A (en) | 2007-07-16 | 2009-02-16 | Lilly Co Eli | Compounds and methods for modulating FXR |
| US8338628B2 (en) | 2007-08-28 | 2012-12-25 | City Of Hope | Method of synthesizing alkylated bile acid derivatives |
| US20090163474A1 (en) | 2007-10-19 | 2009-06-25 | Wyeth | FXR Agonists for the Treatment of Nonalcoholic Fatty Liver and Cholesterol Gallstone Diseases |
| US20090215748A1 (en) | 2007-12-20 | 2009-08-27 | Wyeth | FXR agonists for treating vitamin D associated diseases |
| EP2110374A1 (en) | 2008-04-18 | 2009-10-21 | Merck Sante | Benzofurane, benzothiophene, benzothiazol derivatives as FXR modulators |
| US20100056546A1 (en) | 2008-09-04 | 2010-03-04 | Auspex Pharmaceuticals, Inc. | Sulfonylurea inhibitors of atp-sensitive potassium channels |
| JP2012528170A (ja) * | 2009-05-27 | 2012-11-12 | ブリストル−マイヤーズ スクイブ カンパニー | 別の抗糖尿病薬を用いた先の治療に抵抗性を有する２型糖尿病患者をｓｇｌｔ２阻害剤およびその組成物を用いて治療する方法 |
| EP2289883A1 (en) | 2009-08-19 | 2011-03-02 | Phenex Pharmaceuticals AG | Novel FXR (NR1H4) binding and activity modulating compounds |
| DE112011100657T5 (de) * | 2010-02-24 | 2013-02-28 | Relypsa, Inc. | Amin-polymere zur verwendung als gallensäuresequestriermittel |
| WO2011150285A1 (en) | 2010-05-26 | 2011-12-01 | Adm Tronics Unlimited Inc. | Apparatus and method for uroflowmetry |
| EP2575821B1 (en) * | 2010-05-26 | 2015-08-12 | Satiogen Pharmaceuticals, Inc. | Bile acid recycling inhibitors and satiogens for treatment of diabetes, obesity, and inflammatory gastrointestinal conditions |
| JP5983407B2 (ja) | 2010-09-15 | 2016-08-31 | 住友電気工業株式会社 | レーザ加工方法 |
| WO2012106581A1 (en) | 2011-02-03 | 2012-08-09 | The University Of Chicago | Fxr inhibitor, bile acid sequestrant as combination therapy for cholesterol reduction |
| SI3336097T1 (sl) | 2012-06-19 | 2021-07-30 | Intercept Pharmaceuticals, Inc. | Priprava nekristalinične oblike obetiholne kisline |
| US9814733B2 (en) | 2012-12-31 | 2017-11-14 | A,arin Pharmaceuticals Ireland Limited | Compositions comprising EPA and obeticholic acid and methods of use thereof |
| TN2015000497A1 (en) * | 2013-05-14 | 2017-04-06 | Intercept Pharmaceuticals Inc | 11-hydroxyl-derivatives of bile acids and amino acid conjugates thereof as farnesoid x receptor modulators |
| TW201628625A (zh) | 2015-02-06 | 2016-08-16 | 英特賽普醫藥品公司 | 組合療法醫藥組成物 |
-
2016
- 2016-04-06 US US15/564,799 patent/US10894054B2/en active Active
- 2016-04-06 EA EA201792203A patent/EA036757B1/ru unknown
- 2016-04-06 EP EP16777168.2A patent/EP3280421B1/en active Active
- 2016-04-06 CR CR20170456A patent/CR20170456A/es unknown
- 2016-04-06 MA MA41083A patent/MA41083A1/fr unknown
- 2016-04-06 WO PCT/US2016/026146 patent/WO2016164413A1/en not_active Ceased
- 2016-04-06 CN CN201680029144.7A patent/CN107613986A/zh active Pending
- 2016-04-06 TN TNP/2017/000426A patent/TN2017000426A1/en unknown
- 2016-04-06 ES ES16777168T patent/ES2974281T3/es active Active
- 2016-04-06 MX MX2017012893A patent/MX2017012893A/es unknown
- 2016-04-06 BR BR112017021311A patent/BR112017021311A2/pt not_active IP Right Cessation
- 2016-04-06 SM SM20240104T patent/SMT202400104T1/it unknown
- 2016-04-06 AU AU2016246524A patent/AU2016246524B2/en not_active Ceased
- 2016-04-06 JP JP2017553131A patent/JP6879931B2/ja active Active
- 2016-04-06 CA CA2981507A patent/CA2981507A1/en not_active Abandoned
- 2016-04-06 PE PE2017001987A patent/PE20180034A1/es unknown
- 2016-04-06 KR KR1020177031857A patent/KR20170132879A/ko not_active Ceased
- 2016-04-07 TW TW105110879A patent/TW201642869A/zh unknown
- 2016-04-07 AR ARP160100929A patent/AR104195A1/es unknown
-
2017
- 2017-09-28 IL IL254772A patent/IL254772A0/en unknown
- 2017-10-05 SV SV2017005539A patent/SV2017005539A/es unknown
- 2017-10-05 NI NI201700121A patent/NI201700121A/es unknown
- 2017-10-06 CL CL2017002538A patent/CL2017002538A1/es unknown
- 2017-10-10 CO CONC2017/0010292A patent/CO2017010292A2/es unknown
- 2017-11-01 EC ECIEPI201773004A patent/ECSP17073004A/es unknown
-
2018
- 2018-04-19 CL CL2018001007A patent/CL2018001007A1/es unknown
-
2019
- 2019-07-29 IL IL268316A patent/IL268316B/en unknown
Also Published As
| Publication number | Publication date |
|---|---|
| TN2017000426A1 (en) | 2019-04-12 |
| MX2017012893A (es) | 2018-01-15 |
| WO2016164413A1 (en) | 2016-10-13 |
| SV2017005539A (es) | 2019-01-18 |
| TW201642869A (zh) | 2016-12-16 |
| AU2016246524A1 (en) | 2017-10-26 |
| KR20170132879A (ko) | 2017-12-04 |
| CR20170456A (es) | 2018-06-13 |
| CO2017010292A2 (es) | 2018-01-05 |
| US20180117065A1 (en) | 2018-05-03 |
| EP3280421A4 (en) | 2019-08-28 |
| US10894054B2 (en) | 2021-01-19 |
| EP3280421B1 (en) | 2023-12-27 |
| CA2981507A1 (en) | 2016-10-13 |
| IL254772A0 (en) | 2017-12-31 |
| ES2974281T3 (es) | 2024-06-26 |
| JP2018510900A (ja) | 2018-04-19 |
| AU2016246524B2 (en) | 2021-04-01 |
| PE20180034A1 (es) | 2018-01-09 |
| MA41083A1 (fr) | 2018-05-31 |
| BR112017021311A2 (pt) | 2018-06-26 |
| ECSP17073004A (es) | 2018-02-28 |
| IL268316B (en) | 2022-02-01 |
| EA201792203A1 (ru) | 2018-02-28 |
| NI201700121A (es) | 2018-01-10 |
| CL2017002538A1 (es) | 2018-04-20 |
| EP3280421A1 (en) | 2018-02-14 |
| CL2018001007A1 (es) | 2018-06-15 |
| CN107613986A (zh) | 2018-01-19 |
| AR104195A1 (es) | 2017-07-05 |
| JP6879931B2 (ja) | 2021-06-02 |
| IL268316A (en) | 2019-09-26 |
| EA036757B1 (ru) | 2020-12-17 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| IL268316B (en) | Pharmaceutical preparations for combined treatment | |
| ZA201906613B (en) | Pharmaceutical compositions for combination therapy | |
| ZA201706007B (en) | Pharmaceutical compositions for combination therapy | |
| PL4070787T3 (pl) | Formulacje farmaceutyczne | |
| ZA201905510B (en) | Pharmaceutical compositions for combination therapy | |
| GB201608323D0 (en) | Pharmaceutical compositions | |
| IL256491A (en) | Pharmaceutical formulations | |
| GB201521462D0 (en) | Pharmaceutical composition | |
| GB201506526D0 (en) | Medicinal composition | |
| ZA201707094B (en) | Pharmaceutical formulations | |
| IL255510A (en) | Pharmaceutical compositions | |
| GB201615917D0 (en) | Pharmaceutical composition | |
| GB201515310D0 (en) | Pharmaceutical composition | |
| GB201615914D0 (en) | Pharmaceutical composition | |
| GB201520862D0 (en) | Pharmaceutical composition | |
| IL263999A (en) | Pharmaceutical compositions | |
| GB201615910D0 (en) | Pharmaceutical composition | |
| ZA201500995B (en) | Low dose pharmaceutical composition | |
| ZA201705782B (en) | Pharmaceutical compositions | |
| GB201520762D0 (en) | Novel pharmaceutical compositions | |
| ZA201705783B (en) | Pharmaceutical compositions | |
| PT3319596T (pt) | Composições farmacêuticas | |
| GB201700831D0 (en) | Pharmaceutical compositions | |
| GB201521456D0 (en) | Pharmaceutical composition | |
| GB201609903D0 (en) | Therapeutic compositions |